Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

27 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-02-29

Study Completion Date

2009-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this pilot, exploratory study is to evaluate the safety, tolerance, pharmacokinetics and potential activity of an investigational agent, HE3286, when administered orally, daily for 28 days to patients with mild-to-moderate ulcerative colitis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

NCT06979336

Ulcerative Colitis

RECRUITING PHASE2

Effect of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis

NCT01036022

Colitis, Ulcerative

COMPLETED PHASE2

A Study of JNJ-66525433 in Healthy Participants and Participants With Ulcerative Colitis

NCT04457960

Healthy Colitis, Ulcerative

TERMINATED PHASE1

Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis

NCT01759056

Ulcerative Colitis

COMPLETED PHASE1

Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

NCT02958865

Ulcerative Colitis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

HE3286 has a potentially new mechanism of action that may improve the current therapeutic options available to patients with ulcerative colitis. In preclinical experiments, HE3286 has shown activity in animal models of ulcerative colitis. Additionally, HE3286 has shown to have anti-inflammatory activity associated with corticosteroids but without the side effects associated with corticosteroid use, such as immune suppression and bone loss.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ulcerative Colitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo

2

HE3286 5 mg daily

Group Type EXPERIMENTAL

HE3286

Intervention Type DRUG

daily for 28 days

3

HE3286 10 mg daily

Group Type EXPERIMENTAL

HE3286

Intervention Type DRUG

daily for 28 days

4

HE3286 20 mg daily

Group Type EXPERIMENTAL

HE3286

Intervention Type DRUG

daily for 28 days

5

HE3286 4 mg daily

Group Type EXPERIMENTAL

HE3286

Intervention Type DRUG

daily for 28 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

Intervention Type DRUG

HE3286

daily for 28 days

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Triolex

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18-65 years of age
* Diagnosed (\> 6 weeks) or recently relapsed active mild-to-moderate ulcerative colitis based on colonoscopy or flexible sigmoidoscopy
* Mayo Scoring System for Assessment of Ulcerative Colitis Activity score of 4-9
* Stable dose prior to screening of 6-mercaptopurine (50-150 mg/day 6-MP) \[at least 2 months\], Azathioprine (50-100 mg/day) \[at least 2 months\], and 5-ASA \[at least 2 weeks\]
* For females of reproductive potential, agree to avoid pregnancy during the study and for 3 months following study completion, have a negative serum pregnancy test (b-HCG) at screening and negative urine pregnancy test and use an acceptable method of birth control
* No history of narcotic and/or alcohol abuse within 2 years of screening and agrees to consume \< 6 oz. of wine or equivalent per day
* No experienced renal or liver disease by history and/or based on laboratory results
* Must provide voluntary, written, informed consent prior to screening evaluations and be able to follow verbal and written instructions
* Must be able to swallow capsules

Exclusion Criteria

* Primary sclerosing cholangitis
* Positive for C. difficile toxin in the stool
* Requires hospitalization for treatment of severe ulcerative colitis
* History of clinically significant cardiovascular disease (including coronary artery disease), clinically significant hepatic, respiratory or renal abnormalities, or clinically significant endocrine disorders (not including diabetes)
* Clinically significant abnormalities on laboratory results (renal insufficiency, liver function abnormalities, abnormal WBC or ANC)
* Any clinically significant unstable medical abnormality, chronic disease, or active, serious clinical infection or condition, other than ulcerative colitis
* Uncontrolled hypertension defined as systolic BP \> 160 mmHg and/or diastolic BP \> 100 mmHg on three or more assessment on more than one day(blood pressure must be stable for \> 3 months prior to screening)
* Malignancy within the past 5 years, except for successfully treated basal cell carcinoma of the skin
* Requiring or receiving anti-TNF-a or other immune modulating drugs (other than 6-MP or azathioprine) within 8 weeks prior to screening
* Requiring or receiving any of the following within 4 weeks of the screening visit: interleukins, steroids (i.e., anabolic steroids, glucocorticoids), narcotics, anti-cancer chemotherapeutic agents, metabolic inhibitors or nutraceuticals with immune enhancement claims
* Requiring oral or intravenous cortisone
* Requiring corticosteroid enemas
* Acute illness within 10 days prior to Day 1 or taking antibiotics for UC (but not for a infectious disease) within 14 days of Day 1
* Any clinical condition or receiving therapy that, in the opinion of the Investigator, would make the patient unsuitable for study or unable to comply with the dosing requirements

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No